The concentration of drug distribution industry keeps increasing, and three enterprises are favored

[pharmaceutical network industry trends] under the influence of policies such as two ticket system, zero plus, drug price reduction, volume purchase, etc., the concentration of drug circulation industry will continue to improve, but the increase brought by the accelerated listing of new drugs will compete with the reduction of distribution costs of generic pharmaceutical business, and the industry believes that the performance of circulation enterprises will still maintain a steady growth It is suggested to pay attention to the three national wholesale enterprises of Shanghai pharmaceutical, Jiuzhoutong and Ruikang pharmaceutical Shanghai Pharmaceutical Shanghai Pharmaceutical is a pharmaceutical company listed in Shanghai and Hong Kong Its main business covers pharmaceutical industry, distribution and retail In terms of pharmaceutical retail, Shanghai Pharmaceutical has more than 2000 retail pharmacies distributed all over the country, which are divided into retail chain pharmacies, hospital side pharmacies and professional pharmacies In the first half of 2019, the company's pharmaceutical retail business realized a revenue of 3.837 billion yuan, an increase of 22.43% year on year In addition, in terms of pharmaceutical distribution business, Shanghai Pharmaceutical is an "old hand" in the industry In the first half of 2019, the sales revenue of pharmaceutical distribution business reached 80.194 billion yuan, a year-on-year increase of 21.04%, and the year-on-year growth rate was significantly higher than that of the same period of last year It is worth noting that among the "four major pharmaceutical companies" (i.e Sinopharm holding, China Resources pharmaceutical, Jiuzhoutong and Shanghai Pharmaceutical), Shanghai Pharmaceutical pays special attention to pharmaceutical research and development In 2018, the R & D expenditure was 1.061 billion yuan, a year-on-year increase of 34.22%, accounting for 5.45% of the industrial sales revenue In the first half of 2019, the R & D investment was 564 million yuan, an increase of 17.84% year-on-year, and the high R & D investment continued to be maintained Jiuzhoutong Jiuzhoutong is a private enterprise among the "four major pharmaceutical companies" In the first half of 2019, it has the performance of double growth of revenue and net profit, while the growth of net profit is obvious, reaching 38.46% At present, Jiuzhoutong's marketing network has covered most of China's administrative regions, forming a national network, and has 1132 retail pharmacies (including franchise stores) nationwide On November 26, 2019, kyushutong announced that Huahai "4 + 7" expanded the sales of the winning variety irbesartan tablets through all channels to kyushutong This is also an attempt by Kyushu Tong to actively strive for brand suppliers and their winning varieties under the background of "4 + 7" volume procurement policy and expansion The company said that the mode can give full play to the advantages of distribution resources and marketing ability of kyushutong in all channels, and has positive significance for the expansion of its medical channels According to Ruikang pharmaceutical, Ruikang pharmaceutical is a comprehensive medical service provider that directly sells drugs, medical devices and medical consumables to the national medical institutions, and provides medical information, hospital logistics and hospital logistics services Under the background of "two vote system", the competition of medicine circulation market is intensified and the industry is accelerated to shuffle According to the announcement, from 2015 to 2018, the company acquired 167 consolidated accounts in total, and the total cost of acquiring equity was about 5.34 billion yuan Through these four years of acquisition, the company has become a national circulation pharmaceutical enterprise with annual revenue of 10 billion Data shows that by the end of 2018, Ruikang pharmaceutical has set up nearly 200 subsidiaries in 31 provinces (municipalities directly under the central government), directly serving more than 40000 medical institutions at all levels Since 2018, the company has continued to improve the market share of drug and device circulation business, with sales revenue reaching 33.919 billion yuan, a year-on-year increase of 45.61%, and maintained a growth of more than 40% for four consecutive years.